MyFinsight
Home
Blog
About
Contact
Maturities of marketable
securities
$71,297K
Net cash provided by
(used in) investing...
$22,849K
Canceled cashflow
$48,448K
Net decrease in
cash, cash...
-$48,441K
Canceled cashflow
$22,849K
Accrued expenses and
other current...
$9,376K
Stock-based compensation
expense
$3,939K
Non-cash lease expense
-$293K
Depreciation and
amortization expense
$101K
Prepaid expenses and
other current assets
-$42K
Other non-current
assets
-$27K
Proceeds from the
exercise of stock options
$57K
Purchases of marketable
securities
$48,448K
Net cash used in
operating activities
-$68,310K
Canceled cashflow
$13,778K
Net cash used in
financing activities
-$2,980K
Canceled cashflow
$57K
Net loss
-$78,865K
Accretion of discounts on
investments, net
$1,225K
Non-current clinical
deposits
$1,133K
Accounts payable
-$495K
Operating lease
liabilities
-$282K
Other non-current
liabilities
-$69K
Other
$19K
Payments of deferred
offering costs related to...
$3,037K
Back
Back
Cash Flow
Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. (KLRA)
source: myfinsight.com